Norman Fields Gottscho Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Norman Fields Gottscho Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$273K	Sell	63,380 -7,700	-11%	-$45K	0.08%	58
2026 Q2	$569K	Buy	71,080 +31,230	+78%	+$269K	0.17%	46
2026 Q1	$320K	Buy	+39,850	New	+$382K	0.11%	56

Other funds holding SPRY

General American Investors New York $1.71B AUM 30.1% 1-Year Est. Return

Pavaki Capital Management Pueblo, Colorado $294M AUM 34.46% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $2.18B AUM 12.5% 1-Year Est. Return

Investment Management Associates Greenwood Village, Colorado $490M AUM 6.7% 1-Year Est. Return

Levin Capital Strategies New York $1.42B AUM 19.05% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

American Assets Inc San Diego, California $310M AUM 4.36% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return

Norman Fields Gottscho Capital Management's SPRY Position: Q3 2026 in Review

Norman Fields Gottscho Capital Management reduced its ARS Pharmaceuticals (SPRY) stake by 11% in Q3 2026, selling an estimated $45K and leaving 63,380 shares worth $273K. The position accounts for 0.08% of the portfolio, ranked #58.

Norman Fields Gottscho Capital Management first reported a position in SPRY in Q1 2026 and has held it in 3 quarters since. The position peaked at $569K in Q2 2026. 51 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.

Norman Fields Gottscho Capital Management held 63,380 shares of ARS Pharmaceuticals worth $273K as of Q3 2026.
Norman Fields Gottscho Capital Management sold 7,700 ARS Pharmaceuticals shares in Q3 2026, an estimated $45K.
ARS Pharmaceuticals made up 0.08% of Norman Fields Gottscho Capital Management's portfolio in Q3 2026, its #58 holding.
Norman Fields Gottscho Capital Management first reported a position in ARS Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
Norman Fields Gottscho Capital Management's ARS Pharmaceuticals position peaked at $569K in Q2 2026.
51 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.

Based on Norman Fields Gottscho Capital Management's 13F filing for Q3 2026, filed 5 Oct 2026.